Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases. Verekitug has advanced into three separate world-wide, placebo-controlled, randomized Phase 2 clinical trials, two completed in chronic rhinosinusitis with nasal polyps (CRSwNP) and severe asthma, and one ongoing in chronic obstructive pulmonary disease (COPD).
Last trade$2.07
Day change-$0.085 (-3.95%)
Day range$2.01 – $2.20
Volume830,049
Market cap$118M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$117.84M
Price / earnings
—
Price / book
0.5×
Price / sales
41.06×
EV / sales
24.54×
EV / EBITDA
-0.4×
Profitability
Earnings per share
-$2.99
Return on assets
-66.65%
Return on equity
-70.07%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
20.45×
Quick ratio
20.45×
Cash ratio
3.96×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$168.39M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for UPB, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$395K
$773K
$1.03M
$668K
$683K
$937K
$566K
$613K
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$395K
$773K
$1.03M
$668K
$683K
$937K
$566K
$613K
Selling, general and administrative
$7.17M
$7.05M
$8.08M
$6.67M
$5.54M
$7.42M
$6.78M
$5.16M
Research and development
$36.61M
$36.09M
$36.57M
$40.17M
$32.98M
$37.87M
$25.8M
$21.77M
Total operating expenses
$43.77M
$43.14M
$44.65M
$46.84M
$38.52M
$45.28M
$32.58M
$26.93M
Operating income
-$43.38M
-$42.37M
-$43.62M
-$46.17M
-$37.83M
-$44.35M
-$32.01M
-$26.32M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$41.19M
-$39.7M
-$40.59M
-$42.46M
-$33.75M
-$39.97M
-$27.27M
-$21.24M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$41.19M
-$39.7M
-$40.59M
-$42.46M
-$33.75M
-$39.97M
-$27.27M
-$21.24M
Net income attributable to common shareholders
-$41.19M
-$39.7M
-$40.59M
-$42.46M
-$33.75M
-$39.97M
-$27.27M
-$21.79M
EBITDA
-$43.33M
-$42.32M
-$43.57M
-$46.11M
-$37.79M
-$44.31M
-$31.97M
-$26.27M
Basic earnings per share
-$0.75
-$0.73
-$0.75
-$0.78
-$0.63
-$0.74
-$0.51
-$0.48
Diluted earnings per share
-$0.75
-$0.73
-$0.75
-$0.78
-$0.63
-$0.74
-$0.51
-$0.48
Recent news
Company coverage with links to the original publishers.
Upstream Bio (UPB) reported a quarterly loss of $0.75 per share, missing consensus estimates of $0.67, and posted revenues of $0.4 million, down 41% year-over-year and missing estimates by 49%. The stock has declined 86.8% year-to-date, significantly underperforming the S&P 500's 10.3% gain. The company holds a Zacks Rank #3 (Hold) rating with mixed estimate revisions.
Syndax Pharmaceuticals reported a Q3 loss of $0.55 per share, missing EPS expectations by 5.77%, though it beat revenue estimates with $83.3 million (up 81.5% year-over-year). The stock has underperformed the market by 45.7% year-to-date and carries a Zacks Rank #3 (Hold) rating with mixed estimate revisions.
Upstream Bio announced positive Phase 2 VALIANT trial results for verekitug, a TSLP receptor antagonist, showing a 56% reduction in annualized asthma exacerbation rate at 100 mg every 12 weeks versus placebo. The company plans to initiate Phase 3 trials in Q1 2027 evaluating a 400 mg quarterly dosing regimen in severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP).
Over 65 pharmaceutical companies are advancing 75+ pipeline COPD drugs, with the treatment landscape evolving beyond traditional bronchodilators toward targeted biologics and anti-inflammatory therapies. Recent clinical trial successes include AstraZeneca's tozorakimab meeting primary endpoints in Phase III trials, and multiple companies progressing novel candidates through various development stages.
The severe asthma drug development pipeline shows strong momentum with 30+ pharmaceutical companies actively developing 35+ pipeline therapies across various clinical stages. Key players including AstraZeneca, Generate Biomedicines, GSK, and others are advancing promising candidates targeting thymic stromal lymphopoietin inhibitors and interleukin pathways. Recent approvals and positive trial results, including GSK's Exdensur and Upstream Bio's verekitug, demonstrate progress in addressing this unmet medical need.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.